Cytokinetics, Inc. (NASDAQ:CYTK) announced that its first Phase 2 clinical trial of CK-2127107, a novel fast skeletal muscle troponin activator, in patients with …
Amazon.com,Inc.
Cytokinetics, Inc. (NASDAQ:CYTK) announced that results from the expansion phase of COSMIC-HF (ChronicOral Study of Myosin Activation to Increase Contractility in Heart Failure), a …
Cytokinetics, Inc. (NASDAQ:CYTK) reported total research and development revenues for the third quarter of 2015 were $7.
Cytokinetics, Inc. (NASDAQ:CYTK) and Amgen, Inc.
Analysts weigh in on the biopharmaceutical company Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and biotechnology company Cytokinetics, Inc. (NASDAQ:CYTK), with positive ratings and views.
Recently, various executives have taken part in insider buying activity for the stocks of Tesla Motors Inc (NASDAQ:TSLA), SolarCity Corp (NASDAQ:SCTY), Cytokinetics, Inc. (NASDAQ:CYTK), and Halozyme …
In a research report published Thursday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on shares of Cytokinetics, Inc. (NASDAQ:CYTK) with a price target …
Cytokinetics, Inc. (NASDAQ:CYTK) reported total research and development revenues for the second quarter of 2015 were $6.
In today’s market with most biotech companies sporting bloated valuations it can be hard for investors to find stocks with significant upside. I …
